JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) (USD $)	2 Months Ended	9 Months Ended		98 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	$ 6,000,000	$ 6,000,000		$ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)		600,000
Joint Venture Method Investment Ownership Percentage		60.00%
Joint Venture Investments In Non Voting Preferred Ownership Units		5,000,000
Payments to Acquire Long-term Investments		3,300,000
Joint Venture Investments Common Ownership Units, Coventure (in shares)		400,000
Ownership Percentage Coventure		40.00%
Payments To Acquire Businesses, Net Of Cash Acquired		0	0	4,058,000
Percentage Of Royalty Payment		3.00%
Development Activities Monthly Fee		63,000
Accounting and Administrative Monthly Fee		10,000
Investments In and Advance To Affiliates Additional Performance Measured Incentive Fee		250,000
Joint Venture Losses Recognition Criteria, Common Ownership Equity	0	0		0
Joint Venture, Operating Expenses, Inter Company Transactions	20,000
Joint Venture Operating Expenses Incurred	477,000
Joint Venture, Operating Expenses Allocated To Company	286,000
Income (Loss) Attributable to Noncontrolling Interest		(191,000)
Corporate Joint Venture [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	2,700,000	2,700,000		2,700,000
Lipimetix [Member]
Payments To Acquire Businesses, Net Of Cash Acquired		378,000		4,436,000
Voting Common Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	1,000,000	1,000,000		1,000,000
Non Voting Preferred Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	$ 5,000,000	$ 5,000,000		$ 5,000,000